Skip to main content
. 2024 Jan 14;45:100729. doi: 10.1016/j.ctro.2024.100729

Fig. 1.

Fig. 1

In case A, two metastatic lesions receive MDT at two different time-points. One would have to declare treatment failure at time-point t1, if the classical endpoint PFS were used, in contrast to using FLS, were the situation in case A would not be declared a failure. Case B is hardly oncologically different from A, and at t2, A and B might exhibit the same result.